Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 3.31
QDEL's Cash to Debt is ranked higher than
71% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. QDEL: 3.31 )
QDEL' s 10-Year Cash to Debt Range
Min: 0.09   Max: 13.76
Current: 3.31

0.09
13.76
Equity to Asset 0.81
QDEL's Equity to Asset is ranked higher than
88% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. QDEL: 0.81 )
QDEL' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.88
Current: 0.81

0.52
0.88
Interest Coverage 5.36
QDEL's Interest Coverage is ranked higher than
51% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. QDEL: 5.36 )
QDEL' s 10-Year Interest Coverage Range
Min: 0.8   Max: 68.51
Current: 5.36

0.8
68.51
F-Score: 3
Z-Score: 12.10
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -13.44
QDEL's Operating margin (%) is ranked higher than
66% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. QDEL: -13.44 )
QDEL' s 10-Year Operating margin (%) Range
Min: -13.49   Max: 31.99
Current: -13.44

-13.49
31.99
Net-margin (%) -7.71
QDEL's Net-margin (%) is ranked higher than
68% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. QDEL: -7.71 )
QDEL' s 10-Year Net-margin (%) Range
Min: -13.18   Max: 21.25
Current: -7.71

-13.18
21.25
ROE (%) -5.91
QDEL's ROE (%) is ranked higher than
68% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. QDEL: -5.91 )
QDEL' s 10-Year ROE (%) Range
Min: -11.35   Max: 26.77
Current: -5.91

-11.35
26.77
ROA (%) -4.89
QDEL's ROA (%) is ranked higher than
69% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. QDEL: -4.89 )
QDEL' s 10-Year ROA (%) Range
Min: -8.68   Max: 21.27
Current: -4.89

-8.68
21.27
ROC (Joel Greenblatt) (%) -25.94
QDEL's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. QDEL: -25.94 )
QDEL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -33.72   Max: 144.35
Current: -25.94

-33.72
144.35
Revenue Growth (3Y)(%) 8.10
QDEL's Revenue Growth (3Y)(%) is ranked higher than
79% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. QDEL: 8.10 )
QDEL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.1   Max: 20.6
Current: 8.1

-5.1
20.6
» QDEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

QDEL Guru Trades in Q4 2013

Manning & Napier Advisors, Inc 499,705 sh (+8.14%)
Chuck Royce Sold Out
Mario Gabelli 601,000 sh (-0.35%)
» More
Q1 2014

QDEL Guru Trades in Q1 2014

Mario Gabelli 601,000 sh (unchged)
Manning & Napier Advisors, Inc 12,560 sh (-97.49%)
» More
Q2 2014

QDEL Guru Trades in Q2 2014

Mario Gabelli 601,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
» More
Q3 2014

QDEL Guru Trades in Q3 2014

Paul Tudor Jones 200,000 sh (New)
Mario Gabelli 600,000 sh (-0.17%)
» More
» Details

Insider Trades

Latest Guru Trades with QDEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2012-06-30 Sold Out 0.08%$15 - $18.9 $ 27.6368%0
Joel Greenblatt 2012-03-31 New Buy0.08%$14.18 - $18.24 $ 27.6390%48012
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.30
QDEL's P/B is ranked higher than
72% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. QDEL: 4.30 )
QDEL' s 10-Year P/B Range
Min: 1.07   Max: 6.72
Current: 4.3

1.07
6.72
P/S 5.60
QDEL's P/S is ranked higher than
66% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. QDEL: 5.60 )
QDEL' s 10-Year P/S Range
Min: 1.19   Max: 6.27
Current: 5.6

1.19
6.27
PFCF 153.60
QDEL's PFCF is ranked higher than
79% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QDEL: 153.60 )
QDEL' s 10-Year PFCF Range
Min: 5.91   Max: 393
Current: 153.6

5.91
393
EV-to-EBIT -41.68
QDEL's EV-to-EBIT is ranked higher than
55% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QDEL: -41.68 )
QDEL' s 10-Year EV-to-EBIT Range
Min: -201.7   Max: 276.6
Current: -41.68

-201.7
276.6
Shiller P/E 136.20
QDEL's Shiller P/E is ranked higher than
85% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QDEL: 136.20 )
QDEL' s 10-Year Shiller P/E Range
Min: 22.56   Max: 1297
Current: 136.2

22.56
1297
Current Ratio 2.88
QDEL's Current Ratio is ranked higher than
75% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. QDEL: 2.88 )
QDEL' s 10-Year Current Ratio Range
Min: 1.64   Max: 8.08
Current: 2.88

1.64
8.08
Quick Ratio 2.13
QDEL's Quick Ratio is ranked higher than
71% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. QDEL: 2.13 )
QDEL' s 10-Year Quick Ratio Range
Min: 1.12   Max: 7.07
Current: 2.13

1.12
7.07

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.60
QDEL's Price/Tangible Book is ranked higher than
69% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. QDEL: 10.60 )
QDEL' s 10-Year Price/Tangible Book Range
Min: 1.14   Max: 15.44
Current: 10.6

1.14
15.44
Price/DCF (Projected) 3.10
QDEL's Price/DCF (Projected) is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. QDEL: 3.10 )
QDEL' s 10-Year Price/DCF (Projected) Range
Min: 0.98   Max: 11.48
Current: 3.1

0.98
11.48
Price/Median PS Value 1.50
QDEL's Price/Median PS Value is ranked higher than
69% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. QDEL: 1.50 )
QDEL' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 1.59
Current: 1.5

0.27
1.59
Earnings Yield (Greenblatt) -2.40
QDEL's Earnings Yield (Greenblatt) is ranked higher than
68% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. QDEL: -2.40 )
QDEL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.4   Max: 17.5
Current: -2.4

-2.4
17.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:QL1.Germany,
Quidel Corp was incorporated in the State of Delaware. It commenced operations in 1979. The Company operates in one business segment, which develops, manufactures and markets diagnostic testing solutions for applications mainly in infectious diseases and reproductive and women's health. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. The Company markets its products in the U.S. through a network of national and regional distributors, and a direct sales force. Its diagnostic testing solutions are designed to provide specialized results that serve a broad range of customers, by addressing varying requirements of ease of use, reduced cost, increased test accuracy and reduced time to result. Internationally, the Company sells and markets mainly in Japan, Europe, and the Middle East through exclusive distributor arrangements. During 2012, the Company continued to invest in several key areas: support for clinical research and expanding its communications through promotional campaigns, peer-reviewed technical publications, professional shows and exhibits, symposia, medical education and support of health economics and outcomes research. In 2012, it had manufacturing operations in San Diego and Santa Clara, California and Athens, Ohio Customers for IVD products are mainly centralized laboratories and physician offices and other decentralized non-institutional settings. Its objective is to build a broader-based diagnostic company, with products in market segments that are growing to realize increased shareholder value. The Company competes with several large pharmaceutical and diversified healthcare companies. The testing, manufacture and commercialization of its products are subjected to regulation by numerous governmental authorities, principally the FDA and corresponding state and foreign regulatory agencies.
» More Articles for QDEL

Headlines

Articles On GuruFocus.com
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014 
Quidel Receives FDA Clearance for Its Lyra(TM) Molecular PCR Assay for the Detection of Human Parain Oct 15 2014 
Quidel Receives FDA Clearance for Its Lyra(R) Molecular PCR Assay for the Detection of Adenovirus Oct 15 2014 
Quidel to Hold Third Quarter 2014 Financial Results Conference Call on October 21, 2014 Oct 15 2014 
Top Insider Buys Highlight: Quidel Corporation Jul 28 2014 
Weekly CEO Buys Highlight: TDY, KOPN, QDEL, SALM, FCAL Mar 24 2012 
CEO Buys 6/10/11: Quidel Corp. Jun 10 2011 
Quidel Corp. Reports Operating Results (10-Q) Oct 29 2010 
Quidel Corp. Reports Operating Results (10-Q) Jul 30 2010 
Quidel Corp. (QDEL) CFO John Matthew Radak buys 1,000 Shares Jun 22 2010 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Dec 19 2014
2:01 am Quidel receives simultaneous FDA clearance and CLIA waiver for its Sofia Strep A+... Dec 18 2014
Quidel Receives Simultaneous FDA Clearance and CLIA Waiver for Its Sofia(R) Strep A+ Fluorescent... Dec 17 2014
Quidel Receives Simultaneous FDA Clearance and CLIA Waiver for Its Sofia(R) Strep A+ Fluorescent... Dec 17 2014
Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella... Dec 10 2014
Quidel Receives FDA Clearance for Its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Bordetella... Dec 10 2014
QUIDEL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Dec 08 2014
QUIDEL CORP /DE/ Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 04 2014
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014
Quidel Announces Pricing of $150 Million Convertible Senior Notes Offering Dec 02 2014
Quidel Announces Proposed Offering of $150 Million of Convertible Senior Notes Dec 01 2014
Quidel Announces Proposed Offering of $150 Million of Convertible Senior Notes Dec 01 2014
QUIDEL CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Nov 19 2014
Dr. Kenneth J. Widder Joins Quidel's Board of Directors Nov 18 2014
Dr. Kenneth J. Widder Joins Quidel's Board of Directors Nov 18 2014
QUIDEL CORP /DE/ Financials Oct 30 2014
QUIDEL CORP /DE/ Files SEC form 10-Q, Quarterly Report Oct 24 2014
Quidel beats Street 3Q forecasts Oct 21 2014
Quidel beats Street 3Q forecasts Oct 21 2014
Quidel Corp Earnings Call scheduled for 5:00 pm ET today Oct 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK